MindMed Q2 net loss $29.1M, cash $116.9M; MM-120 GAD topline readout on track for Q4 2023

Definium Therapeutics, Inc.

2023-Q2 EPS reported -$1.41

Net loss of $29.1M in Q2 2023 vs $17.0M in Q2 2022; R&D spend rose to $14.8M ($9.3M prior).
Cash and equivalents $116.9M at June 30, 2023, funding operations into first half of 2025.
MM-120 Phase 2b for GAD enrollment target lowered to 180 patients; topline results expected Q4 2023.
MM-120 Phase 2a for ADHD over 80% enrolled; topline readout expected Q4 2023 / Q1 2024.
Exclusive license agreement with Catalent for Zydis ODT formulation of MM-120 for pivotal trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Definium Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release (the "Press Release:) announcing its financial results for its fiscal quarter ended June 30, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-038033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.